Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma Inc. (COCP) provides this comprehensive news resource for tracking developments in its antiviral therapeutics pipeline. Access official press releases and verified updates on clinical trials, regulatory milestones, and strategic partnerships.
This page serves investors and industry observers seeking timely information about COCP's structure-based drug discovery platform and pipeline progress. Find updates on hepatitis C inhibitors, broad-spectrum influenza treatments, and norovirus antiviral candidates currently in development.
Content includes FDA correspondence, intellectual property filings, preclinical study results, and collaboration announcements with pharmaceutical partners. All materials are sourced directly from company disclosures to ensure regulatory compliance and factual accuracy.
Bookmark this page for consolidated access to Cocrystal Pharma's latest scientific advancements and business developments. Check regularly for updates on their mission to address unmet needs in viral disease treatment through innovative small-molecule therapeutics.
Cocrystal Pharma, Inc. (COCP) announced the appointment of Fred Hassan to its Board of Directors, expanding the board to six members. Hassan brings over 40 years of experience in the pharmaceutical industry, having held senior roles at major companies and investment firms. His recent $2 million investment in Cocrystal via an at-the-market private placement underscores his confidence in the company's prospects.
The Chairman of the Board, Roger Kornberg, expressed optimism that Hassan's expertise will strengthen corporate governance and help advance Cocrystal's antiviral pipeline. Hassan emphasized the company's potential to develop innovative antiviral therapies using a unique structure-based discovery platform. This announcement signals a strategic move for Cocrystal as it aims to enhance its leadership and drive its research efforts towards commercialization.
Cocrystal Pharma (Nasdaq: COCP) announces the acceptance of an oral presentation of new data from its CC-42344 Phase 1 influenza A study at the 7th Annual ISIRV Antiviral Group Conference on May 4, 2023. Dr. Sam Lee, President and co-CEO, will present insights on the first-in-human study of CC-42344, a novel broad-spectrum influenza A polymerase PB2 inhibitor. The company anticipates filing for regulatory approval for a Phase 2a human challenge study later in 2023. CC-42344 has shown potent antiviral activity against various influenza A strains, including those resistant to existing treatments like Tamiflu and Xofluza.
This presentation aligns with the conference theme, “Advancing Respiratory Virus Therapeutics: Lessons Learned from COVID-19.” Cocrystal plans to summarize the data presented and share slides on its website after the conference.
Cocrystal Pharma, Inc. (Nasdaq: COCP) announced a private placement of 2,030,458 shares of common stock at $1.97 per share, raising $4.0 million. The investment was made by notable industry leaders Phillip Frost, M.D., and Fred Hassan, each contributing $2.0 million. This capital infusion strengthens Cocrystal's financial position as it prepares for significant clinical milestones. The company is set to commence a Phase 2a human challenge study for its PB2 inhibitor CC-42344 and a first-in-human trial for its COVID-19 protease inhibitor CDI-988, both pending regulatory approvals. Additionally, a lead candidate in the norovirus program is expected to be selected by mid-2023.
Cocrystal Pharma, Inc. (Nasdaq: COCP) reported financial results for the year ending December 31, 2022, revealing a net loss of $38.8 million, or $4.77 per share, up from $14.2 million, or $0.16 per share in 2021. R&D expenses increased to $12.4 million as the company advanced its antiviral pipeline, including the CC-42344 Phase 1 trial and upcoming CDI-988 Phase 1 trial. Cocrystal plans to submit UK and Australian regulatory filings for influenza and COVID-19 studies, respectively. The company reported unrestricted cash of $37.1 million as of December 31, 2022, with working capital at $39 million.
Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that CFO and co-CEO James Martin will present at the Virtual Investor Summit Conference on March 29, 2023, at 10:30 a.m. Eastern time. The presentation will highlight significant advancements and upcoming milestones in their antiviral programs targeting influenza A, COVID-19, and norovirus. The company employs innovative structure-based technologies to develop novel antiviral therapeutics aimed at viral replication processes.
For more details, interested parties can register for the presentation online.
Cocrystal Pharma, Inc. (Nasdaq: COCP) has announced its participation in several upcoming virtual investment community events. Co-CEO and CFO James Martin will be featured in the Noble Capital Markets’ J.P. Morgan Healthcare Conference Takeaways, available January 26, discussing the biotechnology market and Cocrystal’s opportunities. Additionally, an update on the company’s influenza and COVID-19 antiviral programs will be presented in the C-Suite Interview Series by February 1. Cocrystal will also present at Sequire’s Virtual Biotechnology Conference on February 2 at 11:30 a.m. ET. Cocrystal specializes in developing antiviral therapeutics.
Cocrystal Pharma (Nasdaq: COCP) reported positive results from its Phase 1 study of CC-42344, an oral antiviral targeting influenza A. The study demonstrated favorable safety and tolerability, with no serious adverse events reported. Approximately 50% of subjects experienced mild adverse events, similar to the placebo group. The company plans to apply for regulatory approval to initiate a Phase 2a study in early 2023, targeting potential treatments for pandemic and seasonal influenza, aiming to address significant healthcare costs associated with the illness.
